Tempest Therapeutics, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.36) Per Share (NASDAQ:TPST)

Tempest Therapeutics, Inc. (NASDAQ:TPSTFree Report) – Investment analysts at HC Wainwright issued their Q1 2024 EPS estimates for Tempest Therapeutics in a research report issued to clients and investors on Wednesday, March 20th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($0.36) for the quarter. HC Wainwright has a “Buy” rating and a $47.00 price target on the stock. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Tempest Therapeutics’ Q2 2024 earnings at ($0.36) EPS, Q4 2024 earnings at ($0.42) EPS, FY2027 earnings at $1.24 EPS and FY2028 earnings at $6.13 EPS.

Several other equities analysts have also recently issued reports on the stock. Scotiabank started coverage on shares of Tempest Therapeutics in a research note on Thursday, March 14th. They set a “sector outperform” rating and a $13.00 target price on the stock. William Blair restated an “outperform” rating on shares of Tempest Therapeutics in a research report on Wednesday. Finally, Jefferies Financial Group initiated coverage on Tempest Therapeutics in a research report on Thursday, February 8th. They set a “buy” rating and a $15.00 target price for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $19.00.

Check Out Our Latest Analysis on TPST

Tempest Therapeutics Stock Up 3.7 %

Shares of Tempest Therapeutics stock opened at $3.64 on Thursday. The company’s fifty day simple moving average is $3.82 and its two-hundred day simple moving average is $3.34. The company has a market cap of $80.77 million, a P/E ratio of -1.91 and a beta of -1.75. The company has a current ratio of 4.29, a quick ratio of 1.66 and a debt-to-equity ratio of 0.23. Tempest Therapeutics has a 12-month low of $0.17 and a 12-month high of $9.77.

Hedge Funds Weigh In On Tempest Therapeutics

Hedge funds have recently bought and sold shares of the company. MayTech Global Investments LLC purchased a new stake in Tempest Therapeutics during the 4th quarter worth about $44,000. Susquehanna International Group LLP acquired a new stake in Tempest Therapeutics during the 1st quarter worth approximately $26,000. Millennium Management LLC acquired a new stake in shares of Tempest Therapeutics in the 2nd quarter valued at approximately $29,000. Northern Trust Corp lifted its holdings in shares of Tempest Therapeutics by 147.9% in the 4th quarter. Northern Trust Corp now owns 33,598 shares of the company’s stock valued at $148,000 after buying an additional 20,045 shares during the period. Finally, Worth Venture Partners LLC acquired a new position in Tempest Therapeutics during the second quarter worth $129,000. Institutional investors and hedge funds own 28.73% of the company’s stock.

About Tempest Therapeutics

(Get Free Report)

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.

Featured Stories

Earnings History and Estimates for Tempest Therapeutics (NASDAQ:TPST)

Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.